At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 31 enrolled
Drug / intervention
PTC596drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating PTC596 for Cancer. Completed, enrolled 31 participants across 4 sites in 2 countries.
Detailed Summary
This is a Phase 1, open-label, first-in-human, safety and pharmacokinetic study of PTC596 in patients with advanced cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesCanada, United States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartJan 2016
Primary CompletionFeb 2017
TodayJul 2026
First PostedMar 31, 2015
Enrollment StartJan 1, 2016
Primary CompletionFeb 6, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.3 years ago
Interventions
PTC596drug
PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted